- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: NSCLC, PD-L1, MEDI4736, Tremelimumab, PFS, OS
Total 159664 results
-
AstraZenecaActive, not recruitingNon-Small-Cell Lung Carcinoma NSCLCUnited States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland
-
AstraZenecaActive, not recruitingNon-muscle-invasive Bladder CancerFrance, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
-
AstraZenecaActive, not recruitingNon Small Cell Lung Carcinoma NSCLCPoland, Taiwan, Thailand, Vietnam, United States, Korea, Republic of, Hungary, Russian Federation, Turkey, China, Australia, Netherlands
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Monika Joshi, MDAstraZenecaActive, not recruiting
-
Shadia Jalal, MDAstraZeneca; MedImmune LLC; Big Ten Cancer Research ConsortiumCompleted
-
Wuxi People's HospitalRecruitingCancer | PD-L1 Gene MutationChina
-
AstraZenecaActive, not recruitingCarcinoma, Non-Small-Cell LungPoland, Taiwan, India, Mexico, Russian Federation, Turkey, China, Korea, Republic of, Philippines, Hong Kong
-
Italian Network for Tumor Biotherapy FoundationAstraZenecaUnknownPeritoneal Mesothelioma | Pleural MesotheliomaItaly
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
AstraZenecaCompletedCarcinoma, Non- Small Cell LungUnited States, Canada, France, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Peru, Russian Federation, Hong Kong, Israel, Greece, Australia, Singapore, Turkey, India, A...
-
Swiss Group for Clinical Cancer ResearchCompletedNSCLC Non-small Cell Lung CancerSwitzerland
-
AstraZenecaActive, not recruitingMuscle Invasive Bladder CancerUnited States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
University of Colorado, DenverAstraZenecaWithdrawnPancreatic CancerUnited States
-
Shanghai Zhongshan HospitalRecruiting
-
Baodong QinUnknown
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Inge Marie SvaneCompletedPolycythemia Vera | Essential ThrombocythemiaDenmark
-
German Breast GroupAstraZeneca; CelgeneCompleted
-
Zhongnan HospitalRecruiting
-
Medical University of ViennaUnknownNon Small Cell Lung CancerAustria
-
Hoffmann-La RocheCompletedCarcinoma, Non-Small-Cell Lung | Carcinoma, Small CellUnited Kingdom, Czechia, Germany, Poland, Spain, Switzerland
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Tatarstan Cancer CenterUnknownHereditary Breast CancerRussian Federation
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
University Hospital, AngersCompletedCancer | Sleep Apnea Syndromes, ObstructiveFrance
-
ImmunityBio, Inc.Active, not recruitingSolid Tumor | Metastatic Cancer | Locally Advanced Solid TumorUnited States
-
AstraZenecaActive, not recruitingNon-Small Cell Lung CancerUnited States, Belgium, France, Italy, Spain, United Kingdom, Canada, Hungary, Poland, Thailand, Germany, Korea, Republic of, Czechia, Japan, Philippines, Taiwan, Singapore, Austria
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Lars Møller PedersenCompletedFollicular LymphomaDenmark
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Yale UniversityCompletedBreast NeoplasmsUnited States
-
AstraZenecaRecruitingMuscle Invasive Bladder CancerNetherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
-
Thomas MarronRecruiting
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
MedImmune LLCCompletedDiffuse Large B-Cell LymphomaUnited States, France, United Kingdom, Ireland
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Ludwig Institute for Cancer ResearchBoehringer Ingelheim; MedImmune LLC; PharmaJet, Inc.; CureVac; Cancer Research Institute...CompletedNSCLC | Metastatic Non-small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedEndometrial Cancer | Endometrial Carcinoma | Endometrial Carcinosarcoma | Endometrial Cancer Recurrent | Endometrial Carcinoma, RecurrentUnited States
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Ludwig Institute for Cancer ResearchCancer Research Institute, New York City; MedImmune LLC; Cure Brain Cancer Foundation...CompletedGlioblastomaUnited States, Australia
-
AstraZenecaCompletedCarcinoma, Non-Small-Cell LungUnited States, Canada, Denmark, France, Netherlands, Belgium, Poland, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, Germany, Hong Kong, Spain, Greece, Switzerland, Australia, Isra... and more
-
Ludwig Institute for Cancer ResearchXcovery Holding Company, LLC; Cancer Research Institute, New York City; MedImmune...CompletedCarcinoma | NSCLC | Non-small Cell Lung CancerUnited States
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Sichuan UniversityRecruitingPleural Effusion, Malignant | Peritoneal Carcinoma MetastaticChina
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
King Faisal Specialist Hospital & Research CenterAstraZenecaCompleted